This study aims to explore the preventive effects of dihydromyricetin (DHM) on NAFLD by modulating the intestinal flora and the TLR4/NF-κB signaling pathway. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.